Loading
Life sciences · Journal article
European Journal Pharmaceutical and Medical Research · October 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The progressive loss of muscle mass, strength, and functional ability is the hallmark of skeletal muscular atrophy, a crippling medical condition. Prolonged glucocorticoid therapy, physical inactivity, cancer cachexia, ageing (sarcopenia), and chronic diseases constitute some of the physiological and pathological circumstances that cause it to develop. Chronic inflammation, oxidative stress, mitochondrial dysfunction, impaired protein homeostasis, and activation of proteolytic pathways, such as the ubiquitin–proteasome, autophagy–lysosomal, and apoptotic systems, are some of the interrelated mechanisms involved in the pathogenesis of muscle atrophy. There is mounting evidence that bioactive substances produced from nature may provide useful treatment approaches to prevent muscle atrophy. Among these, ostivone has drawn notice for its strong anti-inflammatory and antioxidant effects as well as its capacity to control anabolic signalling pathways